Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $52.47 USD
Change Today +0.82 / 1.59%
Volume 530.8K
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

resmed inc (RMD) Key Developments

ResMed (UK) Wins Multiple Awardees Contract for Pulse Oximetry, Capnography Devices and Support Products

ResMed (UK) Ltd. won a multiple awardees contract award from NHS Supply Chain acting as agent for NHS Business Services Authority for pulse oximetry, capnography devices and support products. No contract amount was specified (Contract Award Notice No.: 2015/S 154-284086; Lot No.: 1, 2).

ResMed Inc. Declares Quarterly Dividend, Payable on September 17, 2015

The ResMed board of directors declared a quarterly dividend of $0.30 per share, an increase of 7% from the previous dividend. The dividend will have a record date of August 20, 2015, payable on September 17, 2015. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 18, 2015 for common stock holders and for CDI holders.

ResMed Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2015; Provides Earnings Guidance for the Full Year of 2016

ResMed Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended June 30, 2015. For the quarter, the company reported net revenue of $453,064,000 against $415,211,000 a year ago. Income from operations was $99,547,000 against $98,486,000 a year ago. Income before income taxes was $104,116,000 against $106,635,000 a year ago. Net income was $87,462,000 against $87,738,000 a year ago. Diluted earnings per share were $0.61 against $0.61 a year ago. Non-GAAP operating income (excluding the impact of SERVE-HF field safety notice expenses, donations, restructuring expenses and amortization of acquired intangible assets) was $112,686,000 against $107,220,000 a year ago. Non-GAAP net income was $96,379,000 against $93,803,000 a year ago. Non-GAAP diluted earnings per share were $0.68 against $0.66 a year ago. Cash flow from operations was $99.6 million for the quarter, reflecting strong underlying earnings and a modest increase in working capital. Capital expenditure for the quarter was $12.2 million while depreciation and amortization for the quarter totaled $17.7 million. For the year, the company reported net revenue of $1,678,912,000 against $1,554,973,000 a year ago. Income from operations was $409,236,000 against $405,087,000 a year ago. Income before income taxes was $435,916,000 against $431,078,000 a year ago. Net income was $352,886,000 against $345,273,000 a year ago. Diluted earnings per share were $2.47 against $2.39 a year ago. Non-GAAP operating income (excluding the impact of SERVE-HF field safety notice expenses, donations, restructuring expenses and amortization of acquired intangible assets) was $428,933,000 against $421,146,000 a year ago. Non-GAAP net income was $366,754,000 against $356,901,000 a year ago. Non-GAAP diluted earnings per share were $2.57 against $2.47 a year ago. Net cash provided by operating activities was $383,180,000 against $391,268,000 a year ago. Purchases of property, plant and equipment was $62,502,000 against $72,722,000 a year ago. For the fiscal year of 2016, the company expects gross margins to be in a range of 57% to 60%. The company expects SG&A as a percentage of revenue to be in a range of 27% to 28% for fiscal year 2016. R&D expenses is expected as a percentage of revenue to be in a range of 6% to 7% in fiscal year 2016. The effective tax rate for the full fiscal year 2016 will be in the range of 20% to 21%.

ResMed Inc. to Report Q4, 2015 Results on Jul 30, 2015

ResMed Inc. announced that they will report Q4, 2015 results at 1:30 PM, Pacific Standard Time on Jul 30, 2015

ResMed Inc., Q4 2015 Earnings Call, Jul 30, 2015

ResMed Inc., Q4 2015 Earnings Call, Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RMD:US $52.47 USD +0.82

RMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
IDEXX Laboratories Inc $73.21 USD -0.21
MEDNAX Inc $81.57 USD +0.02
Mettler-Toledo International Inc $300.20 USD -5.49
Teleflex Inc $132.49 USD -0.61
Cooper Cos Inc/The $164.74 USD +0.54
View Industry Companies
 

Industry Analysis

RMD

Industry Average

Valuation RMD Industry Range
Price/Earnings 21.2x
Price/Sales 4.4x
Price/Book 4.6x
Price/Cash Flow 20.4x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESMED INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.